ANIP

ANI Pharmaceuticals, Inc.

NasdaqGMUSDEQUITY DELAYED

75.80

▼ 1.52 (1.97%)

MARKET · —

Price

Open

76.65

Prev close

77.32

Day high

77.81

Day low

74.82

Volume

318.21K

Market cap

—

P/E (TTM)

—

52W range

70.15 – 99.50

Trailing performance

Price return · vs SPY

Returnvs SPY

-1.55% -0.2%

-4.05% -7.8%

-8.96% -12.1%

-3.11% -14.2%

YTD

-4.55% -16.8%

-16.85% -36.8%

+26.85% -47.3%

— —

Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.

Fundamentals

TTM · reported

Market cap—

Enterprise value—

Revenue (TTM)—

Gross profit—

EBITDA—

Net income—

EPS (TTM)—

Free cash flow—

Total cash—

Total debt—

Book value / share—

Shares outstanding—

Float—

Short % of float—

Dividend yield—

Beta (5Y)—

Valuation & profitability ratios

Account required

Trailing P/E—

Forward P/E—

PEG ratio—

Price / sales—

Price / book—

EV / revenue—

EV / EBITDA—

Gross margin—

Operating margin—

Profit margin—

Return on equity—

Return on assets—

Debt / equity—

Current ratio—

Free account required

Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.

Create free account Sign in

Analyst targets & ownership

Account required

Mean target—

High target—

Low target—

Implied upside—

Analyst count—

Consensus—

Strong buy / Buy— / —

Hold—

Sell / Strong sell— / —

Held by insiders—

Held by institutions—

Institutions holding—

Free account required

Price targets, consensus spread, insider and institutional ownership.

Create free account Sign in

Moving averages & technicals

Computed from 2Y daily closes

SMA 10

76.03

-0.30% from price

SMA 20

78.06

-3.47% from price

SMA 50

80.31

-6.18% from price

SMA 100

79.97

-5.21% from price

SMA 200

80.08

-5.90% from price

EMA 12

76.98

-1.54% from price

EMA 26

78.13

-2.98% from price

EMA 50

79.09

-4.16% from price

RSI (14)

41.7

Neutral

MACD (12,26,9)

-1.14

Hist -0.02

ATR (14)

2.89

3.84% of price

Realised vol 30D

31.6%

Annualised

Bollinger upper

82.80

20, 2σ

Bollinger lower

73.32

20, 2σ

50 / 200 cross

Golden

80.31 vs 80.08

Trend bias

Below 200

-5.90%

Risk profile

Daily returns · 1Y window

Beta vs SPY

0.24

Less volatile than market

Correlation to SPY

0.10

Largely independent

Realised vol 30D

31.6%

Annualised

Market vol 1Y

12.9%

SPY, annualised

Max drawdown 1Y

-28.7%

Peak to trough

Max drawdown 5Y

-59.4%

Peak to trough

ATR 14

2.89

3.84% of price

Beta (reported)

—

5Y monthly, from filing

Options chain

Account required

ExpirySpot 75.80

Calls

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Puts

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Free account required

Every listed expiry, both sides of the book, with volume, open interest and implied volatility.

Create free account Sign in

Headlines

ANIP · links out to the publisher

The Top 5 Analyst Questions From ANI Pharmaceuticals’s Q2 Earnings Call StockStory · 6d ago Winners And Losers Of Q2: ANI Pharmaceuticals (NASDAQ:ANIP) Vs The Rest Of The Generic Pharmaceuticals Stocks StockStory · 7d ago Should You Buy ANIP as Low Valuation Meets Cortrophin Execution Risk? Zacks · 8d ago ANIP's Cortrophin Guidance Cut Raises the Bar for Second-Half Growth Zacks · 8d ago ANI Pharmaceuticals (ANIP) Q2 2026 Earnings Call Transcript Motley Fool · 8d ago ANIP Q2 Deep Dive: Rare Disease Expansion Drives Growth Amid Guidance Recalibration StockStory · 11d ago ANIP Tops Q2 Earnings, Stock Down on Cortrophin Sales View Cut Zacks · 12d ago ANI Pharmaceuticals (ANIP) Could Be 31% Undervalued On Strong Q2 Results And Guidance Reset Simply Wall St. · 14d ago

PRIVATE STRATEGY · BY QUALIFICATION

The same data. A different seat.

The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.